U.S. ANDA Review Shows India Drug Makers Leading Filer Past Two Years
This article was originally published in PharmAsia News
Executive Summary
A review of U.S. FDA data found that a quarter of filings for approval of generic drugs last year were submitted by India drug makers, more than America-based companies.